Lexicon Pharmaceuticals, Inc. (LXRX): Price and Financial Metrics

Lexicon Pharmaceuticals, Inc. (LXRX)

Today's Latest Price: $1.38 USD

0.04 (-2.82%)

Updated Oct 20 4:00pm

Add LXRX to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

LXRX Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for LXRX is -29.97 -- better than just 0.56% of US stocks.
  • With a price/earnings ratio of 3.87, Lexicon Pharmaceuticals Inc P/E ratio is greater than that of about merely 3.6% of stocks in our set with positive earnings.
  • Revenue growth over the past 12 months for Lexicon Pharmaceuticals Inc comes in at 642.43%, a number that bests 98.76% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Lexicon Pharmaceuticals Inc are CTXS, HPQ, IRWD, GDDY, and KODK.
  • LXRX's SEC filings can be seen here. And to visit Lexicon Pharmaceuticals Inc's official web site, go to www.lexpharma.com.

LXRX Stock Price Chart Interactive Chart >

Price chart for LXRX

LXRX Price/Volume Stats

Current price $1.38 52-week high $5.33
Prev. close $1.42 52-week low $1.37
Day low $1.37 Volume 1,028,400
Day high $1.43 Avg. volume 1,176,905
50-day MA $1.61 Dividend yield N/A
200-day MA $2.15 Market Cap 147.81M

Lexicon Pharmaceuticals, Inc. (LXRX) Company Bio

Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing breakthrough treatments for human disease. Lexicon has clinical-stage drug programs for diabetes and carcinoid syndrome in progress. The company was founded in 1995 and is based in The Woodlands, Texas.

LXRX Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$1.38$4.05 185%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Lexicon Pharmaceuticals Inc. To summarize, we found that Lexicon Pharmaceuticals Inc ranked in the 69th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 186.83% on a DCF basis. As for the metrics that stood out in our discounted cash flow analysis of Lexicon Pharmaceuticals Inc, consider:

  • 38% of the company's capital comes from equity, which is greater than only 18.1% of stocks in our cash flow based forecasting set.
  • Lexicon Pharmaceuticals Inc's weighted average cost of capital (WACC) is 8%; for context, that number is higher than merely 15.51% of tickers in our DCF set.
  • As a business, Lexicon Pharmaceuticals Inc experienced a tax rate of about 0% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than only 0% of stocks generating free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of Lexicon Pharmaceuticals Inc? See ALXN, SGRY, FTLF, GTS, and PDEX.

LXRX Latest News Stream

Event/Time News Detail
Loading, please wait...

LXRX Latest Social Stream

Loading social stream, please wait...

View Full LXRX Social Stream

Latest LXRX News From Around the Web

Below are the latest news stories about Lexicon Pharmaceuticals Inc that investors may wish to consider to help them evaluate LXRX as an investment opportunity.

The Daily Biotech Pulse: Positive Readout From Galapagos, Intersect ENT Strikes Distribution Deal, Sol Gel's Regulatory Filing Accepted For Review

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 10) Agenus Inc (NASDAQ: AGEN ) Akouos Inc (NASDAQ: AKUS ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) ESSA Pharma Inc (NASDAQ: EPIX ) Fortress Biotech (NASDAQ: FBIO ) Harmony Biosciences Holdings Inc (NASDAQ: HRMY ) Inspire Medical Systems Inc (NYSE: INSP ) Kintara Therapeutics Inc (NASDAQ: KTRA ) Kura Oncology Inc (NASDAQ: KURA ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) RedHill Biopharma Ltd (NASDAQ: RDHL ) Silk Road Medical Inc (NASDAQ: SILK ) Shockwave Medical Inc (NASDAQ: SWAV ) Trillium Therapeutics Inc (NASDAQ: TRIL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 10) ADiTx Therapeutics Inc (NASDAQ: ADTX ) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC )(reac...

Benzinga | September 11, 2020

Dosing underway in Lexicon Pharma's mid-stage LX9211 study in diabetic neuropathic pain

Lexicon Pharmaceuticals (LXRX) commences patient dosing with blinded study drug in its RELIEF-DPN-1, a Phase 2 study of LX9211 for the treatment of diabetic peripheral neuropathic pain. The study is designed to enroll ~300 patients. The primary efficacy endpoint under evaluation is the change from baseline (Day 1) to Week 6...

Seeking Alpha | September 4, 2020

Lexicon Pharmaceuticals, Inc. (LXRX) CEO Lonnel Coats on Q2 2020 Results - Earnings Call Transcript

Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2020 Earnings Conference Call July 30, 2020 08:00 ET Company Participants Kimberly Lee - Head, Investor Relations and Corporate Strategy Lonnel Coats - President and Chief Executive Officer Alex Santini - Executive Vice President and Chief Commercial Officer Pablo Lapuerta - Executive Vice President and...

SA Transcripts on Seeking Alpha | July 31, 2020

Lexicon Pharmaceuticals Inc (LXRX) Q2 2020 Earnings Call Transcript

Image source: The Motley Fool. Lexicon Pharmaceuticals Inc (NASDAQ: LXRX)Q2 2020 Earnings CallJul 30, 2020, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorWelcome to the Lexicon Pharmaceuticals Second Quarter 2020 Financial Results and Business Update Conference Call.

Yahoo | July 30, 2020

Is Lexicon Pharmaceuticals (NASDAQ:LXRX) A Risky Investment?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Yahoo | July 30, 2020

Read More 'LXRX' Stories Here

LXRX Price Returns

1-mo -11.54%
3-mo -24.18%
6-mo -32.68%
1-year -59.41%
3-year -87.63%
5-year -86.98%
YTD -66.75%
2019 -37.50%
2018 -32.79%
2017 -28.56%
2016 3.91%
2015 108.95%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8052 seconds.